NCT04123704

Sitravatinib in Metastatic Breast Cancer

A Phase II Study of Sitravatinib in Metastatic, Pre-treated, Triple Negative Breast Cancer

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 3 (actual)
• Sponsor: Xiang Zhang · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study evaluates the efficacy of sitravatinib in patients with metastatic breast cancer. All study participants will receive sitravatinib, 100 mg daily, until their cancer worsens, or until they develop intolerable side effects.

Conditions

• Breast Cancer Stage IV
• Triple Negative Breast Cancer
• Breast Neoplasms
• Breast Cancer Metastatic

Interventions

Type	Name	Description
DRUG	Sitravatinib	sitravatinib capsule

Timeline

• Start date: 2021-09-22
• Primary completion: 2023-01-22
• Completion: 2023-01-22
• First posted: 2019-10-11
• Last updated: 2024-08-26
• Results posted: 2024-08-26

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study